Skip to main content
. 2022 Sep 3;13(9):763. doi: 10.1038/s41419-022-05208-7

Fig. 2. Stable knockdown of SMYD3 suppresses the proliferation of DLBCL cells in vitro and in vivo and increases their sensitivity to doxorubicin in vitro.

Fig. 2

A The mRNA and protein expression levels of SMYD3 in the RL, OCI-LY1, OCI-LY8, RIVA, U2932 and HBL-1 DLBCL cell lines. B Knockdown efficiency of SMYD3 mRNA and protein levels in the OCI-LY1 and OCI-LY8 cell lines. C Knockdown of SMYD3 expression suppressed DLBCL cell proliferation in the OCI-LY1 and OCI-LY8 cell lines. D Tumorigenicity assay of SMYD3-knockdown OCI-LY8 and OCI-LY1 cells. E Hematoxylin and eosin and SMYD3 and Ki67 staining of xenograft tissue samples from mice injected with SMYD3-knockdown OCI-LY8 cells. Magnification, x200. Scale bar, 100 μm. F IC50 values for doxorubicin in OCI-LY1 and OCI-LY8 cell lines were obtained using Cell Counting Kit-8 assays. G SMYD3 knockdown cells proliferated much more slowly after treatment with doxorubicin over a period of 6 days in OCI-LY1 and OCI-LY8 cells.*P < 0.05, **P < 0.01, ***P < 0.001. DLBCL Diffuse large B-cell lymphoma, SMYD3 SET and MYND domain containing 3.